Alembic Pharma Shares Fundamental Analysis and Financial Ratios

Description
The Model covers all the major fundamental aspects of the company over a few years period. The model is easy to edit and update for the future years as well when the company releases its new annual report. The fundamental analysis includes formula based excel model and visualizations of the following:

1. Growth Ratios
2. Profitability Ratios
3. Cash Flow Ratios
4. Liquidity and Solvency Ratios
5. Efficiency Ratios
6. Valuation Multiples (EV/EBIT, Market Cap/EBIT and EV/EBITDA)
7. ROE (Du Pont Analysis)
8. Common Size analysis
9. Enterprise Valuation
10. Financial Strength Analysis

About the company:

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara city of Gujarat – India. Alembic Pharmaceuticals Ltd. is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility – Alembic Research Centre (ARC)-including formulation research, and 150-bed bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad. APL is one of the leading players in the industry to have invested about 11% of its turnover in R&D.As a growth strategy, the company has aggressively started investing in the international generics market with successful ANDA and DMF filings. APL has also filings across Canada, Europe, Australia, South Africa & Brazil. The company caters to the rest of the world markets through branded formulation sales.

The aim is to provide a thorough outlook into the company's financial position. This will help you in projects as well as learning fundamental analysis on their own. This can also be used by Investors who are looking to do their own due diligence before investing in the Indian Stock Markets

(Note: All the research done by us is only for educational purposes and should not be seen as Investment recommendations. We are not SEBI registered Investment Advisors)